Company

Neurozen Co.

Neurozen develops AI-based genetic and neuroimaging services for Alzheimer's risk assessment.

About

Founded in 2015 and based in Seoul, Neurozen develops genetic and AI-powered neuroimaging tools for assessing Alzheimer's disease risk and supporting early detection. Its services include NeuroXRP Genetic Testing and NeuroXgen Alzheimer's Risk Assessment. In 2021, the company raised KRW 3.1 billion in Series A investment.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in